| 000 | 01824 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250514184728.0 | ||
| 264 | 0 | _c20040520 | |
| 008 | 200405s 0 0 eng d | ||
| 022 | _a0022-3417 | ||
| 024 | 7 |
_a10.1002/path.1528 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSpan, Paul N | |
| 245 | 0 | 0 |
_aTissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. _h[electronic resource] |
| 260 |
_bThe Journal of pathology _cApr 2004 |
||
| 300 |
_a395-402 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xmetabolism |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
| 650 | 0 | 4 |
_aRNA, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aTamoxifen _xtherapeutic use |
| 650 | 0 | 4 |
_aTissue Inhibitor of Metalloproteinase-3 _xgenetics |
| 650 | 0 | 4 |
_aTissue Inhibitor of Metalloproteinases _xmetabolism |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aLindberg, Raija L P | |
| 700 | 1 | _aManders, Peggy | |
| 700 | 1 | _aTjan-Heijnen, Vivianne C G | |
| 700 | 1 | _aHeuvel, Joop J T M | |
| 700 | 1 | _aBeex, Louk V A M | |
| 700 | 1 | _aSweep, C G J | |
| 773 | 0 |
_tThe Journal of pathology _gvol. 202 _gno. 4 _gp. 395-402 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/path.1528 _zAvailable from publisher's website |
| 999 |
_c14807938 _d14807938 |
||